UK Markets closed

Bio-Gate AG: Bio-Gate successfully markets antiviral and antibacterial Protective Film Spray for surfaces

·5-min read

DGAP-News: Bio-Gate AG / Key word(s): Product Launch/Miscellaneous
28.10.2020 / 09:00
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Bio-Gate successfully markets antiviral and antibacterial Protective Film Spray for surfaces

- Protective Film Spray from Bio-Gate used for the first time in public transport in Nuremberg
- Advanced negotiations with further potential customers
- Successful commercialization for use in schools, public transport, banks and fitness studios


Nuremberg, 28. October 2020 - Bio-Gate AG (ISIN DE000BGAG981), one of the world's leading suppliers of innovative technologies and individual solutions for health and hygiene, has successfully launched the new antiviral and antibacterial MSGB-Tec Protective Film Spray. The spray is being used in the public transport system in Nuremberg to supplement the existing hygiene measures.

This was preceded by a successful field study in buses, in which the Protective Film Spray showed a high and lasting efficacy. Even more than a week after spraying, a germ reduction of around 90 percent was measured on the handrails, straps, handles and seats of the buses that were tested. This was achieved under the normal, daily use of the buses during passenger transport. In addition to its lasting effect, Bio-Gate's Protective Film Spray is skin-friendly and easy to apply. Besides the handrails and handles, the spray can also be applied to the seats and other textile surfaces. If the technology is applied e.g. directly after basic cleaning, the hygiene status can be maintained or extended for a longer period of time, as cleaning and disinfection measures usually do not last long.

VAG in Nuremberg is one of the first adopters of the MSBG-Tec impregnation spray in Germany, along with another domestic transport company and customers abroad. Follow-up orders are in preparation. The spray application is always verified by a certified test laboratory that checks the effectiveness of the treatment.

The MSGB-Tec Protective Film Spray has been proven to inactivate enveloped viruses. In addition to the current corona virus (SARS-CoV-2), these include SARS-CoV, MERS-CoV and flu viruses. It represents a modern concept for a more sustainable treatment that strengthens the effectiveness of existing cleaning cycles and it is suitable for COVID-19 prevention. The spray also has an antibacterial effect and has an odour-binding technology that immediately reduces unpleasant odours in mass transport vehicles.

The use of Bio-Gate's solutions in public institutions and local public transport is a forward-looking measure to respond to the second wave of increasing COVID-19 infection rates. Especially in public transport, the safety of passengers can be further increased with additional passive hygiene standards. In addition to the use of the spray, Bio-Gate organises regular hygiene monitoring, which is carried out by a certified laboratory from Nuremberg on a random basis in all means of transport or other public facilities.

Thomas Konradt, Director of Business Development at Bio-Gate AG, says: "The MSGB-Tec Protective Film Spray is a registered product, through the use of which our customers achieve a guaranteed high-quality hygiene management in a natural way. Our technology is antiviral, antimicrobial and odour-binding. It also has a lasting effect". Marc Lloret-Grau, CEO, adds: "We are very pleased that we have already convinced the first customers of our solutions. In addition to local and long-distance passenger transport, the Protective Film Spray can also be easily and effectively used in public institutions, schools and cinemas to supplement the existing hygiene strategy in these facilities. In this way, we are making a contribution by providing people in enclosed spaces with the highest possible level of safety during these challenging times and we are enabling a return to normality despite corona".


Contact:
Bio-Gate AG
Neumeyerstr. 28-34
D-90411 Nuremberg, Germany
www.bio-gate.de

North America:
Karl Richter
RFH BioTek Inc.
Tel: 416-407-6120
rfh@rfhBioTek.com
Toronto, Canada

Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Tel +49 (0) 6172 807309
Mobile +49 (0)152 34221966

About Bio-Gate:
The health technology company Bio-Gate AG is one of the world's leading providers of innovative technologies and individual solutions for health and hygiene, which can make living together safer, more carefree and healthier and improve the well-being of every individual. It specialises in equipping materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG refines materials and products, especially in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to make cosmetics, consumer and industrial products, such as paints and varnishes or plastics antimicrobial, thus enhancing them in a unique way.

Disclaimer:

This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the "Shares") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities have already been sold.


28.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Bio-Gate AG

Neumeyerstr. 28-34

90411 Nürnberg

Germany

Phone:

+49 (0) 911 / 47 75 23 - 100

Fax:

+49 (0) 911 / 47 75 23 - 101

E-mail:

marc.lloret-grau@bio-gate.de

Internet:

www.bio-gate.de

ISIN:

DE000BGAG981

WKN:

BGAG98

Listed:

Regulated Unofficial Market in Berlin, Munich, Stuttgart

EQS News ID:

1143538


 

End of News

DGAP News Service

show this
show this